A hybrid approach to re-engineer a SARS-CoV-1 neutralizing antibody against SARS-CoV-2

FHS
August 21, 2023
11:47 am

A hybrid approach involving a combination of conventional discovery and antibody repurposing to combat COVID-19.

Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange – Biotech Investments

EQS-News: Pentixapharm Holding AG / Key word(s): IPO Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of

September 13, 2024

Does tinnitus cause hearing loss in normal hearing individuals?

Whether cochlear neural degeneration occurs in normal-hearing individuals with tinnitus.

December 4, 2023

The big any-day-now biotech news we’re keeping an eye on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.